ERIC REED: Open Payments
NPI 1538555123 · CLEVELAND, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,166 in 68 payments from 12 companies in 2025. Trend: 2023 $731 · 2024 $731 · 2025 $1,166
Food & beverage: $1,166
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $362 |
| Otsuka America Pharmaceutical, Inc. | 10 | $181 |
| E.R. Squibb & Sons, L.L.C. | 12 | $160 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Lundbeck LLC | 3 | $70 |
| Neurocrine BioSciences, Inc. | 4 | $66 |
| Alkermes, Inc. | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 2 | $58 |
| Janssen Pharmaceuticals, Inc | 2 | $45 |
| Sage Therapeutics, LLC | 2 | $40 |
Products named: VRAYLAR, REXULTI, COBENFY, CAPLYTA, INGREZZA, ARISTADA, AUSTEDO XR, ABILIFY MAINTENA.
Industry payments across OH — which companies pay providers there.
